ESTRO 2024 - Abstract Book

S1170

Clinical - Haematology

ESTRO 2024

RT treatment response was evaluated for the cohort of patients. All patients responded to treatment, 6 were in complete response and one had minimal residual disease at the end of the study.

The median follow-up was 44.7 months (range, 16.5 months to 114.4 months); currently, all patients with complete response are disease free.

Conclusion:

Despite the limited number of patients, our study validated the use of the stomach filling protocol in terms of CBCT registration and treatment delivery, with a good control of disease for this group of patients.

Keywords: gastric lymphoma, water protocol, reproductibility

References:

(1) NCCN. B-Cell Lymphomas. National Comprehensive Cancer Network. http:www.nccn.org.

(2) van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004;14:52-64.

2376

Digital Poster

Role of TSEBI at relapse after allogeneic transplant in mycosis fungoides and sezary syndrome

Gabriele Simontacchi 1 , Chiara Mattioli 1 , Francesco Onida 2 , Livia Marrazzo 3 , Doruntina Cela 1 , Stefano Vagge 4 , Concetta Schiavone 4 , Vieri Grandi 5 , Nicola Pimpinelli 5 , Monica Mangoni 1 , Emanuela Olmetto 1 , Debora Chilà 6 , Lorenzo Livi 1 1 Azienda Ospedaliero Universitaria Careggi, Radiation Oncology, Florence, Italy. 2 ASST FBF-Sacco, Ematology Unit, Milan, Italy. 3 Azienda Ospedaliero Universitaria Careggi, Medical Physics Unit, Florence, Italy. 4 E.O. Ospedali Galliera, Radiation Oncology, Genova, Italy. 5 University of Florence, Department of Healt Science, Dermatology Unit, Florence, Italy. 6 University of Florence, Medical Physics Unit, Florence, Italy